RBC Capital Maintains Outperform on NewAmsterdam Pharma Co, Lowers Price Target to $50

Benzinga · 1d ago
RBC Capital analyst Leonid Timashev maintains NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Outperform and lowers the price target from $51 to $50.